scholarly journals Erratum to: The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection

2012 ◽  
Vol 57 (9) ◽  
pp. 2479-2479
Author(s):  
Paul J. Clark ◽  
Alexander J. Thompson ◽  
Qianqian Zhu ◽  
David M. Vock ◽  
Mingfu Zhu ◽  
...  
2012 ◽  
Vol 57 (8) ◽  
pp. 2213-2221 ◽  
Author(s):  
Paul J. Clark ◽  
Alexander J. Thompson ◽  
Qianqian Zhu ◽  
David M. Vock ◽  
Mingfu Zhu ◽  
...  

2015 ◽  
Vol 52 (4) ◽  
pp. 315-320
Author(s):  
Vanessa Aparecida de SANTIS E SILVA ◽  
Maria Lucia G FERRAZ ◽  
Roberto de CARVALHO-FILHO ◽  
Valeria Pereira LANZONI ◽  
Antonio Eduardo Benedito SILVA ◽  
...  

Background - Different factors are responsible for the progression of hepatic fibrosis in chronic infection with hepatitis C virus, but the role of nutritional factors in the progression of the disease is not clearly defined. This study aimed to evaluate the nutritional status and dietary profile among patients with chronic hepatitis C who were candidates for treatment and its association with histopathological features. Methods - A crossectional study was conducted on treatment-naïve patients with chronic hepatitis C genotype 1, between 2011 and 2013. The following assessments were performed before treatment: liver biopsy, anthropometric measurements and qualitative/quantitative analysis of food intake. Results - Seventy patients were studied. The majority of patients was classified as obese (34%) or overweight (20%) according to body mass index [BMI] and as at risk for cardiovascular diseases by waist circumference (79%). Unhealthy food intake was presented by 59% according to qualitative parameters and several patients showed an insufficient intake of calories (59%), excessive intake of protein (36%) and of saturated fat (63%), according to quantitative analysis. With respect to histology, 68% presented activity grade ≥2, 65% had steatosis and 25% exhibited fibrosis stage >2. Comparative analysis between anthropometric parameters and histological features showed that elevated waist circumference was the only variable associated to hepatic steatosis ( P =0.05). There was no association between qualitative and quantitative food intake parameters with histological findings. Conclusion - In this study, most of the patients with hepatitis C presented inadequate qualitative food intake and excessive consumption of saturated fat; in addition, excess of abdominal fat was associated to hepatic steatosis. Therefore, nutritional guidance should be implemented prior to treatment in patients with chronic hepatitis C, in order to avoid nutritional disorders and negative impact on the management of patients.


2012 ◽  
Vol 26 (4) ◽  
pp. 205-210 ◽  
Author(s):  
Kyle J Wilby ◽  
Nilufar Partovi ◽  
Jo-Ann E Ford ◽  
Erica D Greanya ◽  
Eric M Yoshida

OBJECTIVE: To summarize and evaluate the published literature pertaining to boceprevir and telaprevir, and to provide clinicians with suggestions for use in patients with chronic hepatitis C infection.METHODS: A standardized search strategy was performed using the MEDLINE, EMBASE, Google Scholar and International Pharmaceuticals Abstracts databases using the search terms “boceprevir”, “telaprevir”, “boceprevir and hepatitis C” and “telaprevir and hepatitis C”. A manual search of references was performed to identify articles missed by the electronic search. Studies were included in the review if they assessed either boceprevir or telaprevir in comparison with standard of care in chronic hepatitis C patients.RESULTS: The studies identified assessed boceprevir and telaprevir in genotype-1 hepatitis C patients. In both treatment-naive and treatment-experienced patients, sustained virological response rates were achieved more often with boceprevir or telaprevir in combination with pegylated interferon and ribavirin compared with pegylated interferon and ribavirin alone. Both medications were well tolerated, with anemia presenting as the most treatment-limiting adverse effect.CONCLUSIONS: Boceprevir and telaprevir will revolutionize the management of hepatitis C genotype 1 patients and will most likely decrease the burden of end-stage disease worldwide. However, current clinical limitations include establishing appropriate and cost-effective treatment durations, and use in special populations such as transplant patients and patients coinfected with HIV. Future research will need to clarify these clinical obstacles to clearly define the role of these agents in hepatitis C management.


Hepatology ◽  
2003 ◽  
Vol 38 ◽  
pp. 347-347 ◽  
Author(s):  
H CONJEEVARAM ◽  
D KLEINER ◽  
N AFDHAL ◽  
R BROWN ◽  
M FRIED ◽  
...  

2014 ◽  
Vol 146 (5) ◽  
pp. S-921
Author(s):  
John P. Rice ◽  
Amanda Carlson ◽  
David Burnett ◽  
Lisa Cervantes ◽  
Rob Striker ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document